Samaritan CEO Discusses Innovative Drugs and Technologies for Alzheimer's on Radio

		SAMARITAN PHARMACEUTICALS CORPORATE LOGO Samaritan Pharmaceuticals, in collaboration with Georgetown University, develops and strives to commercialize scientific breakthrough innovations for: Alzheimer's (AD) Drugs, to inhibit glucocorticoid-mediated neurotoxicity, an Animal Model to test AD drugs, an AD Diagnostic; a Breast Cancer Diagnostic; a peptide to bind Cholesterol and a late stage Phase II statistically significant HIV drug. Samaritan's patented pipeline is built on a, cholesterol-metabolism and glucocorticoid-biosynthesis, technology platform which is scientifically considered to be a successful therapeutic approach. (PRNewsFoto)[AS] LAS VEGAS, NV USA

LAS VEGAS, Feb. 3 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) is pleased to announce the listing of radio interview of Samaritan's CEO on its website. Listen to an interview with Dr. Janet Greeson discussing Samaritan Pharmaceuticals upcoming drugs for Alzheimer's with Jacqueline Marcell, the host of "Coping with Caregiving" an Internet radio program. http://www.samaritanpharma.com/html/prcoping.html Dr. Janet Greeson, President and CEO of Samaritan Pharmaceuticals stated, "I have so much respect and admiration for Jacqueline Marcell's work. She is an incredibly warm person and inspires you not only to do as much as you can to alleviate the pain and suffering of Alzheimer's patients but to bring some relief to the caregiving families." Alzheimer's Disease Alzheimer's disease is a neurodegenerative condition that affects over 15 million people worldwide, causing memory loss and, ultimately, dementia Alzheimer's usually begins gradually, causing a person to forget recent events or familiar tasks. How rapidly it advances varies from person to person, but the disease eventually leads to confusion, personality and behavior changes and impaired judgment. Communication becomes more difficult as the disease progresses, leaving those affected struggling to find words, finish thoughts or follow directions. Eventually, most people with Alzheimer's disease become unable to care for themselves. (Logo: http://www.newscom.com/cgi-bin/prnh/20030129/SPHCLOGO ) About Samaritan Pharma: "A Little Bridge Can Go a Long Way" Samaritan Pharmaceuticals bridges University bright ideas through drug development, creating a path for promising new drugs, to become commercially viable products. Currently, Samaritan is advancing its, late stage, HIV Immuno-therapeutic drug, with antiviral properties through regulatory affairs, and plans to commence FDA Phase III trials in 2004. At the same time, in collaboration with Georgetown University, Samaritan is advancing a growing pipeline of cholesterol related drugs for AIDS, Alzheimer's, and Cardiovascular diseases through preclinical trials, in preparation, for future growth. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed May 15, 2003. The company undertakes no duty to update forward-looking statements. Samaritan Pharmaceuticals, Inc., 702/735-7001, Fax 702/737-7016 Gene Boyle, Business Development, Email GeneBoyle@aol.com To receive future press releases and newsletters automatically, or for more information, visit our Web site at http://www.samaritanpharmaceuticals.com .